Inside the deadly disease confounding medicine, researchers piecing together clues and the breakthrough that meant survival ...

A tiny antibody component could fundamentally transform the treatment of cystic fibrosis: For the first time, researchers ...

Underwriters were given a 30-day option to purchase up to 1.74 million additional shares. ・Trevi is currently developing Haduvio, its treatment for chronic cough in patients with idiopathic pulmonary ...

This press release shall not constitute an offer to sell, or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which ...

Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy ...

Columnist Kylene Henderson's husband, Donnie, had to pivot in many aspects of life due to PF, including changing his career.

A macrophage that has already fought off one infection does not return to a blank slate. It carries chemical scars, etched ...

A protein called PIEZO1, which is linked to mechanical stress, may play a key role in driving pulmonary fibrosis, a study ...

Avalyn Pharma Inc., (“Avalyn” or the “Company”), a clinical-stage biopharmaceutical company pioneering inhaled therapies to ...

Cautionary Language Concerning Forward-Looking Statements ...

Deupirfenidone slowed the progression of lung disease over 26 weeks in patients with idiopathic pulmonary fibrosis in a clinical trial.

University of Colorado Denver Biomedical Engineering Associate Professor Chelsea Magin is developing a lung model to help ...